Similarly, in the treatment of NSCLC patients, the levels of CD3+, CD4+, and CD8+ cells were higher in the elemene injection plus docetaxel and nedaplatin treatment groups compared with the control group treated with docetaxel plus nedaplatin [143]. Here, CD8A is linked to non-small cell lung carcinoma.